US biotech major Biogen (Nasdaq: BIIB) reported stronger-than-expected earnings for the first quarter of 2025, helped by ...

According to property advisor Knight Frank, venture capital (VC) funding into the UK life sciences sector reached £1.1 ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

The US Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, ...

Enara Bio, a privately-held UK biopharma developing bispecific T-cell engagers, has announced the appointment of Stacey Davis ...

UK investment firm Aviva Capital Partners is supporting a major new life sciences expansion in south London, which aims to ...

US biotech Immunic (Nasdaq: IMUX) has reported top-line results from a mid-stage study of its lead candidate vidofludimus ...

UK pharma major GSK (LSE: GSK) has published results from its Phase III MATINEE trial evaluating Nucala (mepolizumab) in ...

UK regulators are set to review a proposed label update for Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) Alzheimer’s drug ...

The Russian drugmaker Akrikhin has filed a lawsuit against UK pharma major AstraZeneca (LSE: AZN) to the Moscow Intellectual ...

Shares in US drug major Eli Lilly (NYSE: LLY) were a hefty 8% down early Thursday after the Indianapolis firm announced its first quarter financial results and latest guidance for 2025. Revenue in the ...

Shanghai-based biotech Shijian Bio has signed an exclusive option agreement with US firm ConjugateBio to license its EZWi-Fit ...